High-Risk Estrogen-Receptor-Positive Breast Cancer

Is Adjuvant Chemotherapy Useful for Women With Luminal A Breast Cancer?

(2012) Alan S. Coates et al.   JOURNAL OF CLINICAL ONCOLOGY

A Three-Gene Model to Robustly Identify Breast Cancer Molecular Subtypes

(2012) Benjamin Haibe-Kains et al.   JNCI-Journal of the National Cancer Institute

Agreement in Risk Prediction Between the 21-Gene Recurrence Score Assay (Oncotype DX(R)) and the PAM50 Breast Cancer Intrinsic Classifier  in Early-Stage Estrogen Receptor-Positive Breast Cancer

(2012) C. M. Kelly et al.   ONCOLOGIST

Which patients benefit most from adjuvant aromatase inhibitors? Results using a composite measure of prognostic risk in the BIG 1-98 randomized trial

(2011) G. Viale et al.   ANNALS OF ONCOLOGY

Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011

(2011) A. Goldhirsch et al.   ANNALS OF ONCOLOGY

Risk of Recurrence and Chemotherapy Benefit for Patients With Node-Negative, Estrogen Receptor–Positive Breast Cancer: Recurrence Score Alone and Integrated With Pathologic and Clinical Factors

(2011) Gong Tang et al.   JOURNAL OF CLINICAL ONCOLOGY

Prognostic Value of a Combined Estrogen Receptor, Progesterone Receptor, Ki-67, and Human Epidermal Growth Factor Receptor 2 Immunohistochemical Score and Comparison With the Genomic Health Recurrence Score in Early Breast Cancer

(2011) Jack Cuzick et al.   JOURNAL OF CLINICAL ONCOLOGY

Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8·1 years median follow-up

(2011) Meredith M Regan et al.   LANCET ONCOLOGY

Adjuvant Trastuzumab in HER2-Positive Breast Cancer

(2011) Dennis Slamon et al.   NEW ENGLAND JOURNAL OF MEDICINE

Association between breast cancer subtypes and response to neoadjuvant anastrozole

(2011) Anita K. Dunbier et al.   STEROIDS

A Comparison of PAM50 Intrinsic Subtyping with Immunohistochemistry and Clinical Prognostic Factors in Tamoxifen-Treated Estrogen Receptor-Positive Breast Cancer

(2010) T. O. Nielsen et al.   CLINICAL CANCER RESEARCH

Prediction of Risk of Distant Recurrence Using the 21-Gene Recurrence Score in Node-Negative and Node-Positive Postmenopausal Patients With Breast Cancer Treated With Anastrozole or Tamoxifen: A TransATAC Study

(2010) Mitch Dowsett et al.   JOURNAL OF CLINICAL ONCOLOGY

Breast cancer molecular profiling with single sample predictors: a retrospective analysis

(2010) Britta Weigelt et al.   LANCET ONCOLOGY

Deconstructing the molecular portraits of breast cancer

(2010) Aleix Prat et al.   Molecular Oncology

Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2009

(2009) A. Goldhirsch et al.   ANNALS OF ONCOLOGY

Gene expression profiling identifies activated growth factor signaling in poor prognosis (Luminal-B) estrogen receptor positive breast cancer

(2009) Sherene Loi et al.   BMC Medical Genomics

Lessons on responsiveness to adjuvant systemic therapies learned from the neoadjuvant setting

(2009) Marco Colleoni et al.   BREAST

Breast Cancer Subtypes and Response to Docetaxel in Node-Positive Breast Cancer: Use of an Immunohistochemical Definition in the BCIRG 001 Trial

(2009) Judith Hugh et al.   JOURNAL OF CLINICAL ONCOLOGY

Ki67 Expression and Docetaxel Efficacy in Patients With Estrogen Receptor–Positive Breast Cancer

(2009) Frédérique Penault-Llorca et al.   JOURNAL OF CLINICAL ONCOLOGY

Supervised Risk Predictor of Breast Cancer Based on Intrinsic Subtypes

(2009) Joel S. Parker et al.   JOURNAL OF CLINICAL ONCOLOGY

Ki67 Index, HER2 Status, and Prognosis of Patients With Luminal B Breast Cancer

(2009) Maggie C. U. Cheang et al.   JNCI-Journal of the National Cancer Institute